CoChat

A Randomized Withdrawal, Placebo-Controlled Study Evaluating the Efficacy and Tolerability of Tapentadol Extended Release in Patients With Chronic Painful Diabetic Peripheral Neuropathy

Vinik, Aaron I., Shapiro, Douglas Y., Rauschkolb, Christine, Lange, Bernd, Karcher, Keith, Pennett, Deborah, Etropolski, Mila S. · 2014 · Diabetes Care
Cited by 132

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: This study evaluated the efficacy and tolerability of tapentadol extended release (ER) for the management of chronic pain associated with diabetic peripheral neuropathy (DPN). RESEARCH DESIGN AND METHODS: Adults with moderate to severe DPN pain were titrated to tapentadol ER 100–250 mg bid during a 3-week open-label period; patients with ≥1-point reduction in pain intensity (11-point numerical rating scale) at end of titration were randomized to receive placebo or tapentadol ER (optimal dose from titration) for 12 weeks (double-blind, fixed-dose maintenance phase). The primary end point was mean change in average pain intensity from the start to week 12 (last observation carried forward [LOCF]) of the double-blind maintenance phase. RESULTS: A total of 358 patients completed the titration period; 318 patients (placebo, n = 152; tapentadol ER, n = 166) were randomized and received one or more doses of double-blind study medication. Mean (SD) pain intensity (observed case) was 7.33 (1.30) at the start and 4.16 (2.12) at week 3 of the open-label titration period (mean [SD] change, –3.22 [1.97]). The mean (SD) change in pain intensity (LOCF) from start of double-blind treatment to week 12 was as follows: placebo, 1.30 (2.43); tapentadol ER, 0.28 (2.04; least squares mean difference, –0.95 [95% CI –1.42 to –0.49]; P < 0.001). Treatment-emergent adverse events (≥10%) in the tapentadol ER group during the double-blind maintenance phase were nausea (21.1%) and vomiting (12.7%). CONCLUSIONS: Tapentadol ER (100–250 mg bid) was effective and well tolerated for the management of moderate to severe chronic pain associated with DPN.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc13-2291

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 22

  1. Vinik, 2010, The approach to the management of the patient with neuropathic pain, J Clin Endocrinol Metab, 95, 4802, 10.1210/jc.2010-0892 · DOI · Paper page
  2. Dworkin, 2010, Recommendations for the pharmacological management of neuropathic pain: an overview and literature update, Mayo Clin Proc, 85, S3, 10.4065/mcp.2009.0649 · DOI · Paper page
  3. Tzschentke, 2007, (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties, J Pharmacol Exp Ther, 323, 265, 10.1124/jpet.107.126052 · DOI · Paper page
  4. Lee, 2010, A review of SSRIs and SNRIs in neuropathic pain, Expert Opin Pharmacother, 11, 2813, 10.1517/14656566.2010.507192 · DOI
  5. Trescot, 2008, Opioid pharmacology, Pain Physician, 11, S133, 10.36076/ppj.2008/11/S133 · DOI · Paper page
  6. Kroenke, 2009, Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews, Gen Hosp Psychiatry, 31, 206, 10.1016/j.genhosppsych.2008.12.006 · DOI · Paper page
  7. Schwartz, 2011, Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial, Curr Med Res Opin, 27, 151, 10.1185/03007995.2010.537589 · DOI · Paper page
  8. Afilalo, 2010, Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study, Clin Drug Investig, 30, 489, 10.2165/11533440-000000000-00000 · DOI · Paper page
  9. Buynak, 2010, Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study, Expert Opin Pharmacother, 11, 1787, 10.1517/14656566.2010.497720 · DOI · Paper page
  10. Wild, 2010, Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain, Pain Pract, 10, 416, 10.1111/j.1533-2500.2010.00397.x · DOI · Paper page
  11. Zannikos, 2013, Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects, J Opioid Manag, 9, 291, 10.5055/jom.2013.0171 · doi:10.5055/jom.2013.0171
  12. Cleeland, 1994, Pain assessment: global use of the Brief Pain Inventory, Ann Acad Med Singapore, 23, 129
  13. Crawford, 2008, Conceptual adequacy of the neuropathic pain symptom inventory in six countries, Health Qual Life Outcomes, 6, 62, 10.1186/1477-7525-6-62 · DOI
  14. Ware, 1993, SF-36 Health Survey Manual and Interpretation Guide
  15. Wesson, 2003, The Clinical Opiate Withdrawal Scale (COWS), J Psychoactive Drugs, 35, 253, 10.1080/02791072.2003.10400007 · DOI · Paper page
  16. Quessy, 2008, Placebo response in neuropathic pain trials, Pain, 138, 479, 10.1016/j.pain.2008.06.024 · DOI · Paper page
  17. Vinik, 2013, Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin, Clin Ther, 35, 612, 10.1016/j.clinthera.2013.03.008 · DOI
  18. Bouhassira, 2008, Prevalence of chronic pain with neuropathic characteristics in the general population, Pain, 136, 380, 10.1016/j.pain.2007.08.013 · DOI · Paper page
  19. Argoff, 2006, Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain, Mayo Clin Proc, 81, S12, 10.1016/S0025-6196(11)61475-4 · DOI · Paper page
  20. American Society of Pain Educators, 2006, Diabetic peripheral neuropathic pain. Consensus guidelines for treatment, J Fam Pract, 2006, 1
  21. Gálvez, 2013, Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study, Adv Ther, 30, 229, 10.1007/s12325-013-0015-6 · DOI
  22. Steigerwald, 2012, Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study, Curr Med Res Opin, 28, 911, 10.1185/03007995.2012.679254 · DOI

Cited by

Metadata

Authors
Vinik, A. I., Shapiro, D. Y., Rauschkolb, C., Lange, B., Karcher, K., Pennett, D., & Etropolski, M. S.
Venue
Diabetes Care
Published
2014-07-12
Volume
37
Issue
8
Pages
2302-2309
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W1980075122
Cited by
132
References
11
FWCI
7.58
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.